PCOS Is Officially PMOS — A One-Letter Change Aimed at Improving Women's Healthcare

Affecting 170 million people globally, the condition was misnamed for decades — most patients never had ovarian cysts at all.

Polycystic Ovary Syndrome, long the catch-all label for one of the most common endocrine disorders in women, has officially been renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The change, formalized in a paper published May 12 in The Lancet and presented at the European Congress of Endocrinology in Prague, closes fourteen years of debate over a name that researchers and patients had long argued was both clinically inaccurate and structurally harmful.

For an industry building diagnostics, therapeutics, fertility tools, telehealth platforms, and consumer brands around PCOS, the rename is not cosmetic. It triggers a coordinated, multi-year shift in how the condition is classified, diagnosed, reimbursed, researched, and marketed across at least 195 countries.

A name that never matched the disease

The objection to "polycystic ovary syndrome" is older than most of the companies built on it. The label, in use since the 1930s, implied a gynecological disorder defined by ovarian cysts. In practice, neither half of that description holds up.

The follicles visible on ultrasound, long described as "cysts," are not cysts at all. They are arrested follicles — eggs that failed to mature — and pose none of the risks of true ovarian cysts. Many patients diagnosed with the condition do not present with polycystic ovary morphology in the first place. The disease's most consequential features are systemic: insulin resistance, metabolic dysfunction, elevated cardiovascular and type 2 diabetes risk, hyperandrogenism, and a substantially elevated burden of anxiety, depression, and eating disorders.

That mismatch has had measurable consequences. An estimated 70 percent of people with the condition remain undiagnosed worldwide. Patient surveys have consistently shown delays of two or more years and three or more clinicians before diagnosis. The researchers leading the rename effort have argued the name itself is part of the problem, funneling clinical attention to fertility while the metabolic, cardiovascular, and psychological burden compounds.

How the rename happened

The new name is the output of a multi-year global consensus exercise led by Professor Helena Teede of Monash University, with Professor Terhi Piltonen of Oulu University, AE-PCOS Society Executive Director Anuja Dokras, and Rachel Morman, Chair of the UK patient organization Verity. Fifty-six clinical, academic, and patient organizations participated, including the Endocrine Society.

The process used iterative international surveys (drawing more than 14,000 responses from patients and multidisciplinary clinicians), modified Delphi methods, and nominal group technique workshops. Three candidate names made the final shortlist; PMOS was selected by a near-unanimous majority of an 88-member voting panel.

Two dissenting votes came from PCOS Challenge Executive Director Sasha Ottey and PCOS Nutrition Center CEO Angela Grassi, who argued the rename retains "ovarian" despite the condition's broader pathophysiology. Both have driven significant patient-advocacy and policy work over the past decade.

What changes — and what doesn't

The diagnostic criteria themselves are unchanged. PMOS will continue to be diagnosed under the existing framework: oligo-anovulation, hyperandrogenism, and polycystic ovary morphology or elevated anti-Müllerian hormone (AMH), with adolescents required to meet the first two criteria to reduce overdiagnosis.

What changes is the framing, and the framing has structural reach. Clinical guidelines, medical education curricula, and international disease classification systems are all targeted for update. The Lancet paper outlines a staged three-year implementation, with formal integration into the 2028 international guideline cycle. WHO engagement is planned for ICD incorporation, the formal step that triggers downstream updates to billing codes, EHR systems, payer policy, and clinical trial enrollment criteria.

Additional academic papers from the same consortium are being published in parallel, covering adolescent health, maternal health, policy reform, and research priorities. The rename is being positioned as the entry point to a broader recategorization, not its endpoint.

A $15 billion disease, mostly invisible

In the United States alone, the direct healthcare burden of PCOS exceeds $15 billion annually. Diagnostic evaluation accounts for roughly one percent of that total. The rest sits downstream of delayed or missed diagnosis: in treating the diabetes, cardiovascular events, infertility, and mental health conditions that earlier recognition could plausibly mitigate.

Globally, the burden is proportional. A condition affecting 170 million people of reproductive age, predominantly underdiagnosed, with substantial metabolic and cardiovascular sequelae, sits at an unusual intersection: a chronic, high-prevalence disorder treated for decades as a niche gynecological concern.

What the rename means for femtech and women's health

The femtech sector — variously sized between $10 and $60 billion in 2026 depending on the analyst, with double-digit projected growth through the early 2030s — has built a meaningful share of its product, content, and clinical positioning around the PCOS label. At-home hormone testing, ovulation tracking platforms, virtual specialty clinics, supplement brands, AI-enabled diagnostics, and a growing class of metabolic and GLP-1-adjacent therapeutics all reference PCOS as a primary or secondary indication.

The exposure is asymmetric across the sector. For diagnostic and lab providers, the change is largely cosmetic: AMH assays, hormonal panels, and insulin resistance markers don't change, only the category around them does. Pharma and biotech face more involved work — trial registries, regulatory filings, and enrollment criteria all need rewording, and the broader framing of metabolic disease rather than gynecological disorder will shape how indications are positioned to regulators, payers, and prescribers.

The sharpest pressure falls on direct-to-consumer brands and content platforms. PCOS is not just a clinical category in that segment; it is a search term, a community language, an identity marker that has shaped hundreds of brands' product positioning, SEO architecture, and audience acquisition strategy. Keyword equity built over a decade does not transfer cleanly to a new term. The brands that bridge both languages early will own the educational moment; the rest will be pulled through it.

Digital therapeutics and care navigation platforms sit on the other side of the ledger. The rename formalizes what these companies have argued for years: PMOS is a multisystem condition requiring coordinated metabolic, reproductive, and mental health care, not the gynecological frame that has kept integrated-care models commercially marginal. The clinical language has moved closer to the product.

For investors, the rename is less a question of which term portfolio companies adopt in their decks than of whether the underlying clinical positioning reflects the multisystem framework PMOS encodes.

Not everyone is convinced the change goes far enough. Retaining "ovarian" still narrows what is fundamentally a multisystem condition, and forecloses early evidence pointing to a possible male-equivalent form of the syndrome. The dissent was numerically small, but it came from leaders driving much of the field's recent policy momentum.

Adoption velocity is the larger open question. Three-year transitions in clinical terminology rarely move at the pace announced. Payers, EHR vendors, medical schools, regulators, and consumer brands operate on different clocks, and the cost of the change — particularly for businesses with substantial PCOS-anchored brand equity — will create friction. Search behavior will lag clinical adoption by years.

The rename is the most significant nomenclature change in women's endocrine health in a generation, with a three-year implementation timeline backed by the leading clinical and patient organizations in the field. For femtech and women's health, the practical effect is twofold: an immediate update problem across diagnostics, content, and trial infrastructure, and a longer-term repositioning opportunity for a category that has been quietly building toward this moment for years.

PMOS does not change what the disease is. It changes what the field — and the industry built around it — is expected to do about it.